000058357 001__ 58357 000058357 005__ 20210121114502.0 000058357 0247_ $$2doi$$a10.1007/s12094-014-1250-2 000058357 0248_ $$2sideral$$a89517 000058357 037__ $$aART-2015-89517 000058357 041__ $$aeng 000058357 100__ $$aAlés-Martínez, J.E. 000058357 245__ $$aPreventive treatments for breast cancer: recent developments 000058357 260__ $$c2015 000058357 5060_ $$aAccess copy available to the general public$$fUnrestricted 000058357 5203_ $$aBreast cancer is a burden for western societies, and an increasing one in emerging economies, because of its high incidence and enormous psychological, social, sanitary and economic costs. However, breast cancer is a preventable disease in a significant proportion. Recent developments in the armamentarium of effective drugs for breast cancer prevention (namely exemestane and anastrozole), the new recommendation from the National Institute for Health and Care Excellence to use preventative drugs in women at high risk as well as updated Guidelines from the US Preventive Services Task Force and the American Society of Clinical Oncology should give renewed momentum to the pharmacological prevention of breast cancer. In this article we review recent major developments in the field and examine their ongoing repercussion for breast cancer prevention. As a practical example, the potential impact of preventive measures in Spain is evaluated and a course of practical actions is delineated. 000058357 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000058357 590__ $$a2.075$$b2015 000058357 591__ $$aONCOLOGY$$b153 / 213 = 0.718$$c2015$$dQ3$$eT3 000058357 592__ $$a0.865$$b2015 000058357 593__ $$aMedicine (miscellaneous)$$c2015$$dQ2 000058357 593__ $$aOncology$$c2015$$dQ2 000058357 593__ $$aCancer Research$$c2015$$dQ3 000058357 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000058357 700__ $$aRuiz, A. 000058357 700__ $$aChacón, J.I. 000058357 700__ $$aLluch Hernández, A. 000058357 700__ $$aRamos, M. 000058357 700__ $$aCórdoba, O. 000058357 700__ $$aAguirre, E. 000058357 700__ $$aBarnadas, A. 000058357 700__ $$aJara, C. 000058357 700__ $$aGonzález, S. 000058357 700__ $$aPlazaola, A. 000058357 700__ $$aFlorián, J. 000058357 700__ $$0(orcid)0000-0003-0123-4274$$aAndrés, R.$$uUniversidad de Zaragoza 000058357 700__ $$aSánchez Rovira, P. 000058357 700__ $$aFrau, A. 000058357 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000058357 773__ $$g17, 4 (2015), 257-263$$pClin. transl. oncol.$$tClinical and Translational Oncology$$x1699-048X 000058357 8564_ $$s183900$$uhttps://zaguan.unizar.es/record/58357/files/texto_completo.pdf$$yVersión publicada 000058357 8564_ $$s78739$$uhttps://zaguan.unizar.es/record/58357/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000058357 909CO $$ooai:zaguan.unizar.es:58357$$particulos$$pdriver 000058357 951__ $$a2021-01-21-10:52:00 000058357 980__ $$aARTICLE